[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitiligo---macular-depigmentation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitiligo---macular-depigmentation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100635148","phase-2-comparative-study-of-microneedling-with-topical-minoxidil-5--nb-uvb-in-stable-vitiligo-100635148",false,"NCT07548918","Comparative Study of Microneedling With Topical Minoxidil 5% ± NB-UVB in Stable Vitiligo\"","Comparative Clinical and Histopathological Study of Microneedling With Topical Minoxidil 5% Versus Microneedling With Topical Minoxidil 5% Combined With Narrow-Band Ultraviolet B Phototherapy in the Treatment of Stable Vitiligo","Inclusion Criteria:\n\n* Patients with stable non-segmental vitiligo\n* No new lesions\n* No enlargement of existing lesions\n* Patients of both sexes\n* Age 16 years or older\n\nExclusion Criteria:\n\n* Active vitiligo\n* Pregnant or lactating women\n* History of keloid formation\n* Hematological disorders\n* Coagulopathies\n* Use of anticoagulant therapy\n* Use of medications that may prolong bleeding\n* Previous vitiligo treatment in the last 2 months",true,"ALL","16 Years","60 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study is a randomized controlled trial comparing microneedling with topical minoxidil 5% versus microneedling with minoxidil combined with NB-UVB phototherapy in stable vitiligo.\n\nIt aims to evaluate both clinical and histopathological outcomes in 30 patients with non-segmental stable vitiligo.\n\nVitiligo is a chronic depigmenting disorder caused by melanocyte destruction with significant psychosocial impact.\n\nThe study also investigates immunohistochemical changes, particularly Wnt\u002Fβ-catenin signaling expression in lesional skin.\n\nThe combination therapy is expected to enhance repigmentation by improving melanocyte activation, drug delivery, and angiogenesis",[28],"Vitiligo - Macular Depigmentation","NOT_YET_RECRUITING","2026-04-23",{"date":32,"type":33},"2026-04-29","ACTUAL",{"date":35,"type":22},"2026-05-20",{"date":37,"type":22},"2027-10-15",{"name":39,"class":40},"Sohag University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100594182","phase-2-0005-latanoprost-gel-for-nonsegmental-vitiligo-100594182","NCT07016113","0.005% Latanoprost Gel for Nonsegmental Vitiligo","Comparison of the Effectiveness Between a Combination of 0.005% Latanoprost Gel With 308 nm Excimer Phototherapy and a Combination of 0.1% Mometasone Furoate Cream With 308 nm Excimer Phototherapy on Repigmentation of Nonsegmental Vitiligo in Children","Inclusion Criteria:\n\n* Patients with non-segmental vitiligo.\n* Patients with stable vitiligo for at least 6 months based on the Vitiligo Disease Activity (VIDA) score.\n* Aged 10-17 years.\n* Affected area \\\u003C10%.\n* Having at least two lesions to be treated. The vitiligo lesions selected for treatment must meet the following criteria:\n\n  1. Relatively the same size, ranging from a minimum of 1 cm² to 4 cm².\n  2. Bilateral location on both sides of the body.\n  3. A minimum distance of 5 cm between the studied lesions and other vitiligo lesions.\n  4. Not located on the palms, soles, or genital area.\n\nExclusion Criteria:\n\n* Use of topical therapy (corticosteroids, calcineurin inhibitors, psoralen, and antioxidants) for at least 2 weeks before the study, systemic therapy (corticosteroids, antioxidants, and vitamin D) for at least 4 weeks before the study, and phototherapy for at least 4 weeks before the study.\n* Presence of other active autoimmune diseases such as type 1 diabetes mellitus, thyroid disease, alopecia areata, rheumatoid arthritis, or Addison's disease, based on medical history and physical examination.\n* History of or current skin cancer, photosensitivity, or undergoing radiotherapy.\n* Allergy or contraindication to topical corticosteroids or latanoprost.\n* History of hypertension, asthma, diabetes mellitus, anemia, kidney, liver, neurological, or cardiovascular diseases.","10 Years","17 Years",{"count":51,"type":22},10,[25],"Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation. PGF2α has been shown to stimulate the growth of melanocyte dendrites, increasing dendricity even at low doses, as well as enhancing tyrosinase activity and quantity, thereby promoting repigmentation. Studies on the use of 0.005% latanoprost gel in both children and adults with vitiligo have demonstrated effective repigmentation without reported side effects.",[28],[56,57],"Latanoprost","Vitiligo","2025-06-03",{"date":60,"type":33},"2025-06-11",{"date":62,"type":22},"2025-07-01",{"date":64,"type":22},"2025-11-30",{"name":66,"class":40},"Universitas Padjadjaran",1]